Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)-Reference-Cited by-同舟云学术

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

Published:2010-07-15 Issue:2 Volume:123 Page:453-461
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Pritchard Kathleen I.,Rolski Janusz,Papai Zsuzsanna,Mauriac Louis,Cardoso Fatima,Chang Jose,Panasci Lawrence,Ianuli Carmen,Kahan Zsuzsanna,Fukase Kenjiro,Lindemann Justin P. O.,Macpherson Merran P.,Neven Patrick

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-1022-9.pdf

Reference14 articles.

1. Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7:17–28

2. Howell A (2006) Fulvestrant (‘Faslodex’): current and future role in breast cancer management. Crit Rev Oncol Hematol 57:265–273

3. Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403

4. Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386–3395

5. Robertson JFR (2007) Fulvestrant (Faslodex)—how to make a good drug better. Oncologist 12:774–784

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer;European Journal of Medicinal Chemistry;2024-01

2. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer;Journal of Clinical Oncology;2023-08-20

3. Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier;Cancers;2022-10-19

4. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer;Nature Communications;2022-07-15

5. Design and synthesis of a novel ZB716-d6 as a stable isotopically labeled internal standard;Synthetic Communications;2022-06-18